摘要
背景与目的肺癌是目前世界范围内造成死亡人数最多的癌症之一,而肺腺癌是其主要分型。DEPDC1(DEP domain containing 1)被证实与多数肿瘤的发生发展密切相关,DEPDC1在肺腺癌中过表达已被初步证实,本研究旨在探究DEPDC1的表达与肺腺癌临床预后的关系,对DEPDC1作为肺腺癌潜在生物标志物和治疗靶点的可能性进行初步探讨。方法利用生物信息学网站GEPIA搜集相关信息,在线分析DEPDC1表达与患者预后生存关系。收集本医院患者资料,对收集的样本进行免疫组化染色,并进行统计学分析。随后,体外培养肺腺癌系细胞,通过Western blot与逆转录定量聚合酶链反应(reverse transcription-quantitative polymerase chain reaction, RT-q PCR)验证敲低效率,再进行细胞增殖的实验。结果 DEPDC1在肺腺癌组织中表达显著高于癌旁正常组织,DEPDC1在肺腺癌组织中高表达,DEPDC1高表达与肺腺癌的肿瘤大小临床分期相关,敲低DEPDC1可抑制A549和H1975细胞增殖。结论 DEPDC1在肺腺癌的进展演变中扮演着重要角色,有望成为肺腺癌重要的治疗靶点和一个潜在的新的生物标志物。
Background and objective Lung cancer is the leading cause of death worldwide, and lung adenocarcinoma is the main subtype of lung cancer. DEP domain-containing 1(DEPDC1) has been proved to be closely related to the occurrence and development of most tumors, and the overexpression of DEPDC1 in lung adenocarcinoma has been preliminarily confirmed. This study aims to explore the relationship between the expression of DEPDC1 and the clinical prognosis of lung adenocarcinoma, and to preliminarily explore the possibility of DEPDC1 as a potential biomarker and therapeutic target of lung adenocarcinoma. Methods The bioinformatics website GEPIA database was used to collect relevant information, and the prognostic was analyzed online. Patient data were collected for statistical analysis, and immunohistochemical staining was performed on the collected samples. Subsequently, lung adenocarcinoma cells were cultured in vitro, and the knockout efficiency was verified by Western blot and reverse transcription-quantitative polymerase chain reaction(RT-q PCR), and cell proliferation experiments were performed. Results The expression of DEPDC1 in lung adenocarcinoma tissues is significantly higher than that in adjacent normal tissues. The high expression of DEPDC1 is correlated with the tumor size and clinical stage of lung adenocarcinoma and knocking down DEPDC1 inhibits the proliferation of A549 and H1975 cells. Conclusion DEPDC1 plays an important role in the progression and evolution of lung adenocarcinoma. And it is expected to become an important therapeutic target and a potential new biomarker for lung adenocarcinoma.
作者
沈健
郗萌萌
Jian SHEN;Mengmeng XI(Department of Rheumatology and Immunology,The Third Affiliated Hospital of Jinzhou Medical University,121001 Jinzhou,China;Department of Respiratory Medicine,Jinzhou Women and Infant Hospital,121001 Jinzhou,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2021年第7期453-460,共8页
Chinese Journal of Lung Cancer
